📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-12 18:44
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharma for ₹67.19 Cr
Tavexia Lifecare Limited has announced the acquisition of a 60% controlling equity stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore. The transaction will be executed via cash subscription of 2,09,97,180 fresh equity shares at ₹32 per share, granting Tavexia access to a manufacturing unit in MIDC Tarapur, Maharashtra. The ₹67.19 Crore transaction is massive relative to Tavexia's scale, exceeding 200% of its TTM revenue of ₹32 Crore and net worth of ₹43 Crore. To finance the purchase, the company plans to initiate strategic fund-raising via equity or convertible instruments.
Confidence: HIGH
What changedTavexia's board approved acquiring 60% of Meyonex Pharma for ₹67.19 Crore in cash and expanded its corporate objects to include APIs, formulations, and CDMO services.
Why it mattersThe deal marks a major business transformation into active pharma manufacturing, but financing it requires capital exceeding the company's entire current net worth.
Acquisition Value: ₹67.19 CroreEquity Stake: 60%Shares to Subscribe: 2,09,97,180Issue Price per Share: ₹32Deal vs TTM Revenue: ~210%Deal vs Net Worth: ~156%
📅 Short termMarket attention will focus on the details and pricing of the proposed equity/convertible fund-raising needed to pay the ₹67.19 Crore purchase consideration.
📈 Long termIf successfully funded and integrated, the Tarapur manufacturing facility pivots the business from low-margin distribution into APIs, formulations, and CDMO verticals.
⚠ Risk flags
- High dilution risk as the deal size (₹67.19 Cr) significantly exceeds the company's net worth (₹43 Cr)
- Low promoter holding of 6.39% raises governance and control dilution concerns
- Operational execution and integration risk of pivoting into manufacturing
Key Highlights
Acquiring a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 Crore
Subscription of 2,09,97,180 fresh equity shares at an issue price of ₹32 per share
Deal value represents ~210% of TTM revenue (₹32 Cr) and exceeds net worth (₹43 Cr)
Target brings an operational manufacturing base in MIDC Tarapur, Maharashtra
Financing planned via fresh strategic fund-raising through equity or convertible instruments
👀 What to Watch
Track shareholder approvals and announcements detailing the planned fundraise structure, as substantial equity dilution is likely required to fund this ₹67.19 Crore acquisition.
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharma for ₹67.19 Cr
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for ₹67.19 crore via cash subscription. The transaction involves subscribing to 2,09,97,180 fresh equity shares at ₹32 per share, giving Tavexia access to a manufacturing facility in MIDC Tarapur, Maharashtra. The deal size of ₹67.19 crore is massive relative to Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore. To fund the purchase, the company plans to raise capital through equity or convertible instruments.
Confidence: HIGH
What changedTavexia Lifecare signed an agreement to acquire a 60% controlling stake in Meyonex Pharmaceuticals for ₹67.19 crore and altered its Main Object Clause to expand into APIs, formulations, and CDMO services.
Why it mattersThe acquisition significantly pivots the micro-cap distributor into active pharmaceutical manufacturing, but requires funding that exceeds its current net worth (₹43 crore) and TTM revenue (₹32 crore).
Acquisition stake: 60%Total consideration: ₹67.19 CroreShares to be acquired: 2,09,97,180Issue price per share: ₹32Deal value vs TTM revenue: ~210%Deal value vs Net Worth: ~156%
📅 Short termThe market will monitor the details of the proposed equity/convertible fundraise required to finance the acquisition.
📈 Long termIf successfully funded and executed, the MIDC Tarapur facility could meaningfully scale revenue into formulations and CDMO, though execution risk is high given low promoter holding (6.39%) and existing negative operating margins.
⚠ Risk flags
- Substantial equity dilution risk given the deal value exceeds current net worth
- Execution and integration risk entering complex pharma manufacturing
- Very low promoter holding at 6.39%
Key Highlights
Acquiring 60% controlling equity stake in Meyonex Pharmaceuticals Limited
Total deal consideration of ₹67.19 Crore via cash subscription
Subscribing to 2,09,97,180 fresh equity shares at an issue price of ₹32 per share
Gains manufacturing operations located in MIDC Tarapur, Maharashtra
Deal value represents ~210% of TTM revenue (₹32 Cr) and ~156% of net worth (₹43 Cr)
👀 What to Watch
Track shareholder approvals and announcements detailing the specific fundraising mechanism, pricing, and potential equity dilution required to fund the ₹67.19 crore cash consideration.
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharma for ₹67.19 Cr
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for an all-cash consideration of ₹67.19 crore. The transaction involves subscribing to 2,09,97,180 fresh equity shares of Meyonex at ₹32 per share. To finance this acquisition, which significantly exceeds Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore, the Board approved an in-principle fundraise via equity, warrants, or debt. Meyonex reported a turnover of ₹10.79 crore in FY25.
Confidence: HIGH
What changedBoard approved the acquisition of 60% of Meyonex Pharmaceuticals for ₹67.19 crore via fresh equity subscription and initiated plans for an associated fundraise.
Why it mattersThe deal value (₹67.19 crore) is more than double Tavexia's TTM revenue of ₹32 crore and 1.5x its net worth, implying major dilution or leverage to fund the takeover.
Acquisition cost: ₹67,19,09,760Acquisition cost vs Net worth: ~156%Acquisition cost vs TTM revenue: ~210%Stake acquired: 60.00%Meyonex FY25 turnover: Rs. 10,79215000/-
📅 Short termMarket attention will focus on details of the financing plan, particularly potential equity dilution risks for retail shareholders given the tiny promoter holding (6.4%).
📈 Long termIf successfully integrated and funded without excessive equity dilution, the acquisition shifts the company towards pharmaceutical manufacturing, though Meyonex's recent turnover shows a declining trend.
⚠ Risk flags
- High dilution risk: Deal size exceeds company's entire net worth and requires external fundraising
- Target financial trajectory: Meyonex revenue declined in FY25 compared to FY24
- Low promoter holding (6.4%) in the acquirer company
Key Highlights
Proposed acquisition of 60% post-allotment equity stake (2,09,97,180 shares) in Meyonex Pharmaceuticals Limited
Total cash consideration fixed at ₹67,19,09,760 at an issue price of ₹32 per share
In-principle approval to raise funds via preferential issue, rights issue, or debt to fund the deal
Target entity reported FY25 turnover of ₹10,79,21,500 compared to ₹13,32,07,500 in FY24
👀 What to Watch
Track the upcoming board announcements regarding the specific mode, quantum, and dilution terms of the proposed ₹67.19 crore fundraise, as well as the execution of definitive agreements.
Tavexia Lifecare to Acquire 60% Stake in Meyonex Pharma for ₹67.19 Cr
Tavexia Lifecare's Board approved the acquisition of a 60% controlling stake in Meyonex Pharmaceuticals Limited for an all-cash consideration of ₹67.19 crore. The transaction involves subscribing to 2,09,97,180 fresh equity shares of Meyonex at ₹32 per share. To finance this acquisition, which significantly exceeds Tavexia's TTM revenue of ₹32 crore and net worth of ₹43 crore, the Board approved an in-principle fundraise via equity, warrants, or debt. Meyonex reported a turnover of ₹10.79 crore in FY25.
Confidence: HIGH
What changedBoard approved the acquisition of 60% of Meyonex Pharmaceuticals for ₹67.19 crore via fresh equity subscription and initiated plans for an associated fundraise.
Why it mattersThe deal value (₹67.19 crore) is more than double Tavexia's TTM revenue of ₹32 crore and 1.5x its net worth, implying major dilution or leverage to fund the takeover.
Acquisition cost: ₹67,19,09,760Acquisition cost vs Net worth: ~156%Acquisition cost vs TTM revenue: ~210%Stake acquired: 60.00%Meyonex FY25 turnover: Rs. 10,79215000/-
📅 Short termMarket attention will focus on details of the financing plan, particularly potential equity dilution risks for retail shareholders given the tiny promoter holding (6.4%).
📈 Long termIf successfully integrated and funded without excessive equity dilution, the acquisition shifts the company towards pharmaceutical manufacturing, though Meyonex's recent turnover shows a declining trend.
⚠ Risk flags
- High dilution risk: Deal size exceeds company's entire net worth and requires external fundraising
- Target financial trajectory: Meyonex revenue declined in FY25 compared to FY24
- Low promoter holding (6.4%) in the acquirer company
Key Highlights
Proposed acquisition of 60% post-allotment equity stake (2,09,97,180 shares) in Meyonex Pharmaceuticals Limited
Total cash consideration fixed at ₹67,19,09,760 at an issue price of ₹32 per share
In-principle approval to raise funds via preferential issue, rights issue, or debt to fund the deal
Target entity reported FY25 turnover of ₹10,79,21,500 compared to ₹13,32,07,500 in FY24
👀 What to Watch
Track the upcoming board announcements regarding the specific mode, quantum, and dilution terms of the proposed ₹67.19 crore fundraise, as well as the execution of definitive agreements.
Tavexia Lifecare Board to Meet on Oct 7, 2026 to Review Up to 60% Stake Acquisition in Meyonex Pharma
Tavexia Lifecare has scheduled a Board meeting on October 7, 2026, to deliberate on the proposed acquisition of up to 60% equity in Meyonex Pharmaceuticals Limited. This follows an initial approval granted on September 7, 2026, which authorised preliminary evaluation, valuation, and due diligence. For a micro-cap company with a market cap of approximately ₹1 crore and TTM revenue of ₹32 crore, acquiring a controlling stake could significantly alter its operational footprint. Additionally, the trading window has been closed from September 30, 2026, ahead of the half-year results.
Confidence: HIGH
What changedThe Board is reconvening to deliberate on due diligence findings and decide the next course of action for acquiring up to a 60% stake in Meyonex Pharmaceuticals.
Why it mattersAcquiring a controlling stake could materially reshape the company's business scale, given Tavexia's micro-cap size (₹1 crore market cap) and negative operating margins (-15.9%).
Proposed equity stake: up to 60%Board meeting date: 07th October, 2026Prior approval date: 07th September, 2026Trading window closure start date: September 30, 2026
📅 Short termMarket focus will remain on the October 7 meeting outcome, particularly regarding deal size and transaction structure.
📈 Long termIf successfully executed, the acquisition of an unlisted pharmaceutical business could alter business scale, but integration and financing risks remain elevated given the low promoter holding (6.39%).
⚠ Risk flags
- Dilution risk if financed via fresh equity issuance
- Lack of disclosed deal valuation and target financials
- Very low promoter holding (6.39%)
Key Highlights
Board meeting scheduled for October 7, 2026, to discuss proposed acquisition
Target is up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited
Follows earlier board approval dated September 7, 2026, for due diligence and valuation
Trading window closed from September 30, 2026, until 48 hours after H1 results
👀 What to Watch
Track the outcome of the October 7 Board meeting for deal valuations, mode of funding (cash vs share swap/dilution), and acquisition timelines.
Sattva Sukun Lifecare Reports Q1 FY27 Results; Utilizes Rs 18.92 Cr Rights Issue Proceeds
Sattva Sukun Lifecare approved its Q1 FY27 financial results and provided an update on its July 2025 Rights Issue. The company raised Rs 19.16 crore and has successfully utilized Rs 18.92 crore (approx. 98.7%) as of June 30, 2026. A significant portion of the funds, Rs 11.94 crore, was directed toward strategic investment in its subsidiary, PavaPuri Export Private Limited. Despite the large fund deployment, the company remains a micro-cap with a market capitalization of only Rs 1 crore and a low promoter holding of 6.4%.
Confidence: HIGH
What changedThe company has nearly completed the utilization of its 2025 Rights Issue proceeds, shifting from a fund-raising phase to an operational execution phase.
Why it mattersThe fundraise of Rs 19.16 crore is massive relative to the company's current Rs 1 crore market cap (approx 19x), indicating a significant attempt to pivot or scale the business through its subsidiary.
Rights Issue Amount Raised: Rs 19.16 crTotal Funds Utilized: Rs 18.91 crInvestment in Subsidiary: Rs 11.94 crFundraise vs Market Cap: 1916%Business Expansion Funding: Rs 3.00 cr
📅 Short termThe stock may remain volatile due to its micro-cap nature; the market will wait for the full Q1 financial tables to assess operational health.
📈 Long termLong-term viability depends on the performance of PavaPuri Export Private Limited and the efficiency of the newly acquired factory and land assets.
⚠ Risk flags
- Extremely low promoter holding (6.4%)
- Micro-cap liquidity risk (Rs 1 Cr market cap)
- Negative TTM operating margins (-15.9%)
Key Highlights
Raised Rs 19.16 crore through a Rights Issue completed on July 7, 2025
Utilized Rs 18.92 crore of the total proceeds as of the quarter ended June 30, 2026
Invested Rs 11.94 crore into subsidiary M/s PavaPuri Export Private Limited for strategic growth
Allocated Rs 3.00 crore for business expansion, including acquisition of office premises, factory, and land
Reported zero deviation in the use of funds compared to the modified objects of the issue
👀 What to Watch
Investors should focus on the upcoming detailed P&L statement to see if the deployment of Rs 18.92 crore is translating into revenue growth or margin improvement, especially given the TTM OPM of -15.9%.
Rs 19.16 Cr Rights Issue: Sattva Sukun Reports 98.7% Fund Utilization as of June 2026
Sattva Sukun Lifecare (formerly Mayukh Dealtrade) approved its Q1 FY27 results and reviewed the utilization of Rs 19.16 Cr raised via a Rights Issue in July 2025. As of June 30, 2026, the company has deployed Rs 18.91 Cr, representing 98.7% of the total funds raised. A significant portion of the proceeds, Rs 11.94 Cr, was directed toward a strategic investment in its subsidiary, PavaPuri Export Private Limited, while Rs 3.00 Cr was used for business expansion including office and factory premises.
Confidence: HIGH
What changedThe company has nearly completed the deployment of capital from its 2025 Rights Issue, shifting focus from fund-raising to asset utilization in its subsidiary and physical infrastructure.
Why it mattersFor a company with a market capitalization of only Rs 1 Cr, the deployment of Rs 19 Cr is massive (19x market cap). The success of these investments is critical for the company's turnaround, given its current negative operating margins (-15.9%).
Rights Issue Proceeds: Rs 19.16 CrTotal Utilized (to date): Rs 18.91 CrInvestment in Subsidiary: Rs 11.94 CrProceeds vs Market Cap: 1916%Promoter Holding: 6.39%
📅 Short termNeutral. The market will likely wait for the full Q1 FY27 financial results to see if the capital deployment is translating into revenue growth or margin improvement.
📈 Long termThe company is attempting to scale through its subsidiary and new physical assets. However, the high deviation from original funding targets and low promoter skin-in-the-game are long-term structural risks.
⚠ Risk flags
- Extremely low promoter holding (6.4%)
- Significant deviation from original Rights Issue objects
- Micro-cap liquidity risk
- Negative operating margins (-15.9%)
Key Highlights
Rs 19.16 Cr total funds raised via Rights Issue on July 7, 2025.
Rs 18.91 Cr total funds utilized as of June 30, 2026, leaving a balance of Rs 0.24 Cr.
Rs 11.94 Cr invested in subsidiary M/s PavaPuri Export Private Limited, the largest single allocation.
Rs 3.00 Cr deployed for business expansion including acquisition of office premises, factory, and land.
Original fund-raising target of Rs 49.50 Cr was significantly scaled down to Rs 19.16 Cr.
👀 What to Watch
Investors should monitor the operational performance of the subsidiary PavaPuri Export Private Limited, as it has absorbed over 60% of the capital raised. The company's extremely low promoter holding (6.4%) and micro-cap status warrant caution.
